Background: Urachal carcinomas occur mostly in the bladder dome, comprising 22% to 35% of vesical adenocarcinomas, and are generally treated by partial cystectomy with en bloc resection of the median umbilical ligament and umbilicus. Detailed pathologic studies with clinical outcome correlation are few.
U rachal carcinoma is rare and comprises 0.35% to 0.7% of all bladder cancers and 22% to 35% of vesical adenocarcinomas. 17, 19 The first extensive description of this entity was made by Begg 2 in 1931. Its rarity has translated into a very limited number of published clinicopathologic series, especially in the pathology literature. 13, 15 The urachus is a vestigial structure that connects the bladder to the allantois during early embryonic development. After birth it becomes a fibrous cord known as the median umbilical ligament. If remnants of the allantois remain within the ligament, they may develop into cysts and epithelial neoplasms. Urachal remnants have been identified in one-third of cases in postmortem studies; in the dome and anterior wall commonly and rarely in the posterior wall of the bladder. 2, 18 The urachus has intramucosal, intramuscular, and supravesical segments. It contains 3 distinct tissue layers: an epithelial canal lined by urothelium, submucosal connective tissues, and an outer layer of smooth muscle. Urachal neoplasms can arise in any of these layers, and can be epithelial or mesenchymal. Similar to urothelium at other sites, the epithelium often demonstrates focal glandular metaplasia, and this provides a morphologic basis for the development of intestinal-type tumors. 2, 18 The criteria for a diagnosis of urachal carcinoma are somewhat controversial but most investigators agree with those set forth by Sheldon et al 19 and Mostofi et al. 14 These include (a) tumor in the dome of the bladder; (b) absence of cystitis cystica and cystitis glandularis; (c) predominant invasion of the muscularis or deeper tissues with a sharp demarcation between the tumor and surface bladder urothelium that is free of glandular or polypoid proliferation; (d) presence of urachal remnants within the tumor; (e) extension of tumor into the bladder wall with involvement of the space of Retzius, anterior abdominal wall, or umbilicus; and (f) no evidence of a primary neoplasm elsewhere. A few staging systems have recently been proposed, 13, 16 but commonly followed is that proposed by Sheldon et al 19 : pT1-no invasion beyond the urachal mucosa; pT2-invasion confined to the urachus; pT3-local extension to the (a) bladder, (b) abdominal wall, and (c) viscera other than the bladder; and pT4-metastasis to (a) regional lymph nodes and (b) distant sites.
The mainstay of treatment for these tumors is partial cystectomy with en bloc resection of the median umbilical ligament up to the umbilicus. 9 There are conflicting results in the literature on whether prognosis and survival are worse for urachal as compared with nonurachal bladder adenocarcinoma. 7, 14, 24 Because of the silent nature of early lesions, their propensity for local growth, and the tendency to metastasize late in the clinical course, a large proportion of patients with carcinomas of urachal origin present with disease at stage pT3 or higher.
Very few studies have comprehensively described the clinicopathologic features with outcome correlation as a case series. The goal of this study was to carry out a detailed morphologic assessment of this entity, and correlate it with staging and outcome parameters.
MATERIALS AND METHODS
Approval to perform this study was obtained from the institutional review board and the human tissue utilization committee. A total of 67 tumors located in the dome of the urinary bladder diagnosed and treated at Memorial Sloan Kettering Cancer Center by radical cystectomy or partial cystectomy between 1984 and 2005 were identified. Hematoxylin and eosin-stained slides were obtained from the pathology files of Memorial Sloan Kettering Cancer Center. Of the 67 cases, 24 cases fulfilled the histologic criteria for urachal carcinoma. We used the following 4 histologic criteria, modified from the Sheldon criteria, for inclusion in our cohort: 1. Location of the tumor in the dome/anterior wall 2. Epicenter of carcinoma in the bladder wall 3. Absence of widespread cystitis cystica/glandularis beyond the dome/anterior wall 4. Absence of a known primary elsewhere This cohort was smaller than that described in a recent study of urachal carcinoma from our institution by Herr et al, 9 where the definition of ''urachal'' included all dome-based tumors for which the therapeutic approach was similar.
Patient demographics, clinical history, treatment, and follow-up details, including outcome information, were obtained from the patient charts. We reviewed all biopsies, transurethral resection specimens, and the partial or radical cystectomy specimens with the corresponding pelvic lymph node dissections. The gross findings including the size and geographical location of the tumor were noted from the pathology reports. The morphologic characteristics of the carcinoma including location in the bladder wall, histologic subtype and invasion pattern, the presence and characteristics of the urachal remnants, and the presence and location of associated cystitis cystica and glandularis were recorded. The presence of lymphovascular invasion, status of margins, and peritoneal involvement or lack thereof were also noted. Pathologic staging was performed according to the staging system of Sheldon et al. 19 A panel of immunohistochemical stains was performed on a representative formalin-fixed paraffinembedded tumor block from 15 of the 24 cases where adequate tumor was available for evaluation. These included CK7 (monoclonal; DAKO, Carpinteria, CA); CK20 (monoclonal, DAKO, Carpinteria, CA); 34BE12 (monoclonal; DAKO, Carpinteria, CA); CDX-2 (monoclonal; Biogenex, San Ramon, CA), and b-catenin (monoclonal, Ventana). For CK7, CK20, and 34BE12, any cytoplasmic staining was interpreted as positive (focal, when only patchy staining of the tumor cells was present or diffuse, when the majority of the tumor cells in most fields stained uniformly and strongly). For CDX-2, any nuclear staining was considered positive. For b-catenin, both cytoplasmic membranous positivity and any nuclear immunoreactivity were evaluated. A control sample set of colonic adenocarcinoma cases available on a tissue microarray was also stained for 34BE12 and b-catenin.
RESULTS
The patient demographics and individual clinicopathologic features of the cases are tabulated in Tables 1 and 2. The mean age of the patients at diagnosis was 52 years (range: 26 to 68 y). Fifteen patients were male and 9 were female (male to female ratio 1.7:1). The breakdown of the initial surgical procedure performed is as follows: partial cystectomy with or without a bilateral pelvic lymph node dissection in 9 cases, an extended partial cystectomy with resection of the umbilicus with or without a pelvic lymph node dissection in 11 cases, a radical cystectomy in 1 case, radical cystoprostatectomy in 2 cases, and a resection of a presumptive urachal cyst in 1 case. In 6 cases (cases 5, 8, 11, 12, 17, and 24), surgery was followed by chemotherapy. In addition, cases 8, 10, and 24 also received adjuvant radiation therapy. The tumor was located in the dome of the bladder in 23 cases, and the dome and anterior wall in 1. The overlying urothelium was involved by adenocarcinoma in 3 cases. In all 3, urachal remnants were identified (Fig. 1 ), and showed a transition from benign to adenomatous epithelium ( Fig. 2 , inset). Lymphovascular invasion was identified in 2 cases.
The breakdown of disease stage at the time of definitive surgery was as follows: pT1 (0 cases), pT2 (2 cases), pT3a (8 cases), pT3b (11 cases), pT3c (1 case), pT4a (1 case), and pT4b (1 case). Seven of 24 (29%) patients recurred locally. The histologic features are tabulated in Table 3 and demonstrated in Figures 3A-D. On histology, 13 showed adenocarcinoma not otherwise specified (NOS) and 9 were adenocarcinoma with enteric/colonic differentiation, 1 of these also with signet ring cells. One case each showed adenocarcinoma mixed with urothelial carcinoma with clear cell features and lymphoepithelioma-like carcinoma. There was no case of predominant urothelial carcinoma, NOS. The immunohistochemical staining results are summarized in Table 4 and demonstrated in Figures 4A-B . The mean follow-up period was 43 months (range: 0.9 to 155.6 mo). The clinical outcome data are summarized in Table 5 . Twenty-nine percent (7/24) of the cases recurred. The time interval to recurrence from initial surgery ranged from 9.6 to 22 months (range: 13.9 mo). Sites of recurrence included urinary bladder (5 cases), prostate into the prostatic ducts and seminal vesicles (1 case), prostate along with prostatic and membranous urethra (1 case), retroperitoneal soft tissue (1 case), and pubic bone (1 case). The breakdown of disease stage in these 15 Benign ''transitional'' 6* Adenomatous 9 Invasion pattern 24 No invasion 2 Pushing 2 Infiltrating 20 Cystitis cystica/cystitis glandularis 9 Cystitis cystica 5 Cystitis glandularis 4 7 patients was pT3a (3 cases) and pT3b (4 cases). Five of these 7 patients eventually died of the disease (pT3a-2 and pT3b-3). The other 2 remain alive with no evidence of disease after 18.2 and 92.1 months follow-up. The first of these 2 underwent an extended partial cystectomy with umbilical resection and pelvic lymph node dissection, whereas the second had a partial cystectomy followed by multiple recurrences along the distal urothelial tract for which he subsequently received radiation therapy.
Distant metastases occurred in 9 patients (37.5%). In 4 of the 9 cases, distant metastases occurred without prior local recurrence. Three patients were pT3a, 4 patients were stage pT3b, and 1 patient each was pT4a and pT4b. The most common sites of metastases were regional lymph node and lungs (4 instances each), followed by peritoneum and anterior abdominal wall, bone and soft tissue, and in 1 instance, the ovary. The time interval between initial diagnosis and metastases ranged from 0 to 132.8 months (average 28.7 mo).
Seven patients (29%) died of the disease. The breakdown of pathologic stage in this patient cohort is as follows: pT3a (3 cases), pT3b (3 cases), and pT4b (1 case). Five of these 7 had local recurrences in the urinary bladder and distant metastases before death. The remaining 2 had only distant metastases before death. Of the other 2 patients with distant metastases, 1 was alive with disease and 1 had no evidence of disease. Interestingly, 2 patients had multiple local recurrences in the form of seeding in the genitourinary tract. The first patient (case 10) was a 65-year-old man who was diagnosed with a urachal adenocarcinoma located in the dome of the bladder for which a partial cystectomy was performed. Surgical pathology evaluation showed surface involvement in the form of a villous adenoma. There was also a positive soft tissue margin for which the patient underwent external beam radiotherapy. Five years later the patient was found to have palpable disease in his prostate and a biopsy was consistent with adenocarcinoma morphologically similar to his urachal carcinoma. The patient was also found to have a nodule in the abdominal wall and subsequently underwent an en bloc resection of the abdominal wall recurrence and a cystoprostatectomy. Final pathology revealed extensive involvement of the prostate, prostatic urethra, and the seminal vesicles. The histology of the recurrent in situ carcinoma was similar to that of the primary. Immunohistochemical studies demonstrated the tumor to be positive for CK20 and negative for CK7, prostate-specific antigen, and prostaticspecific acid phosphatase, supporting the fact that it was not prostate cancer.
The second patient (case 24) was a 62-year-old man with a long-standing history of prostatitis who presented with gross hematuria. A cystoscopic examination revealed a tumor in the dome of the bladder for which he underwent a partial cystectomy with retroperitoneal lymph node dissection. Pathologic examination showed a villous tumor arising within a urachal remnant in the muscularis propria of the dome protruding into the lumen of the urinary bladder ( Fig. 1B) . One year later, he once again had hematuria for which he underwent cystoscopy with local resection of 5 small papillary tumors. For the next 7 years he had several episodes of bloody mucus discharges for which he was treated with transurethral resections. The histology in all of these recurrences was adenocarcinoma that was morphologically similar to the patient's original tumor. As the tumor was purely noninvasive, it seemed to represent seeding from the original tumor. An immunostain for prostate-specific antigen performed on 1 of the specimens was negative, thus arguing against a prostatic origin. Eventually cystoprostatectomy with an ileal conduit placement was performed.
The pathology revealed moderately differentiated adenocarcinoma involving the prostatic urethra, the proximal membranous urethra, and prostate gland, with extension along the prostatic ducts. The urinary bladder did not contain any tumor. There was no vascular invasion and the margins were negative. Three years later, he developed local recurrence in the right retropubic region, for which he received radiation therapy. Four months later, follow-up computed tomography scans revealed that he had stable disease in the right suprapubic region, but developed a lesion that was abutting the spleen, for which he received chemotherapy.
All 15 urachal tumors we studied were strongly and diffusely CK20 positive, whereas positive staining for CK7 was present in about half. Only 10 of the 15 tumors studied (66%) stained with 34BE12, and in the majority 
DISCUSSION
Herr and collaborators 9 recently reported 50 cases of urachal carcinoma from our institution. However this was strictly a clinical study, where all dome-based tumors were considered urachal, the logic being that the therapeutic approach would be similar in all cases. In the current study, the case selection process was much more rigorous and took into account the topographic and pathologic features of each case, and therefore, included a smaller number of cases. The pathologic criteria proposed by Sheldon et al 19 and Mostofi et al 14 for the diagnosis of urachal carcinoma are considered somewhat restrictive. Certainly a deviation from the first 2, that is, (1) tumor in the dome of the bladder and (2) absence of cystitis cystica and cystitis glandularis, does not preclude a diagnosis of urachal carcinoma. This is supported by the fact that urachal remnants have been observed in the midline or vertex in only 54% of patients whereas they have reportedly been identified in the anterior wall in 2%. 18 Schubert et al 18 have also identified them in the posterior wall in 14%. However the latter is difficult to explain as the majority of tumors arising in these remnants are known to be dome-based, 10,14 with a minority centered in the anterior wall. This was also true of our series where, in 23 cases, the location was the dome. Only 1 of the tumors additionally involved the anterior wall along with the dome. It is possible that remnants in some of the cases mentioned by Schubert et al may be other epithelial vestiges located in the posterior wall.
In the literature, whereas adenocarcinomas of the bladder have a relatively higher incidence in women as compared with urothelial carcinomas, most series on urachal carcinomas have reported a higher incidence in men. 10, 11 Hematuria was the most common presenting symptom, followed by a palpable suprapubic mass and mucosuria. 19 In our series, men were affected to a greater extent (15 men vs. 9 women). The most common clinical presentation was gross hematuria (15 cases), which is similar to vesical adenocarcinoma. Less frequent present-ing symptoms included bloody and mucoid urethral discharge, draining mucoid sinus to skin, recurrent urinary tract infections, abdominal mass, and obstructive urinary symptoms.
In published series, the commonest histologic subtype of urachal carcinoma is adenocarcinoma with enteric features with or without mucin production. 10, 17 Some of the adenocarcinomas have a signet ring component in the form of signet ring cells in association to extravasated mucin, and some have the morphology of colloid carcinomas. Squamous cell carcinoma and typical urothelial and anaplastic carcinomas may also arise in the urachus. 6, 19 Villous adenomas of the urachus have been reported, sometimes associated with mucosuria, which suggests a continuity with the bladder lumen. 4 Rarely mesenchymal neoplasms may also originate from these vestigial remnants, 22 although we did not identify any. According to some investigators, 10 there is no association between prognosis and tumor type (colloid vs. enteric/ colonic), the degree of differentiation, and the presence and amount of signet ring cells. Others 1 have reported tumors with lower grade to be strongly correlated with lower disease stage and better outcome.
In our series, the most frequent histologic subtype was adenocarcinoma, NOS (13 cases; 50%). Adenocarcinomas of the enteric type with a variable component of signet ring cells and mucinous features made up 9 cases (37.5%). No cases of ''true'' signet ring cell carcinoma (tumor with diffuse infiltrative growth, diffuse wall thickening, and devoid of extracellular mucin) were identified. Within the adenocarcinoma category, the differentiation of the tumor, presence or absence of mucin production, or the presence or absence of signet ring cells did not seem to influence outcome, although the number of cases were too small to draw any definite conclusions. We observed 2 cases in which the adenocarcinoma component was dominant, but a secondary component made up a significant portion of the tumor. In 1 of these, the secondary component was a urothelial carcinoma with clear cell features (Fig. 3C) . Another case had a striking lymphoepithelioma-like carcinoma component (Fig. 3D ). Both tumors were high stage (pT3a and pT3b, respectively). In the case with lymphoepitheliomalike carcinoma features, the patient was node negative and remains disease free after initial extended partial cystectomy with umbilical resection and lymph node dissection after 42.1 months of follow-up. The small number of cases with unusual histology in this series does not make it possible to assess differences in biologic behavior on the basis of histologic subtype of the tumor.
We noted the presence of cystitis cystica in 5 cases (21%) and cystitis glandularis in 4 (17%). In all of these cases except 1, this finding was only focal and predominantly in the bladder overlying the urachal neoplasm. One case had exuberant cystitis glandularis in the transurethral resection but not in the partial cystectomy. In no instance did we find any dysplasia or transition to malignancy in these foci of proliferative cystitis. Other authors 10 have also reported the occasional presence of proliferative cystitis in cases with urachal carcinoma. It must be borne in mind that the changes of proliferative cystitis are very common in normal bladder and are thought to be either a reactive phenomenon to local inflammation or variants of normal histology and possess virtually no malignant potential in this setting. It is thought that their presence in bladders with cancer may be coincidental or the cancer itself may be producing the local inflammatory insult that causes them. 5 The presence or absence of benign remnants has not been recorded consistently in the existing literature. Johnson et al 10 state that in their series of 14 patients, urachal rests were identified in none, and they cite the reason as the extent of the tumor. We identified definitive urachal remnants in 15 of our 24 cases (62.5%) ( Table 3) . Two other cases had bulky tumors extending through the wall of the bladder partly obliterating circumscribed structures suggestive of urachal remnants. An additional problem, in our experience, is that seldom do the histologic sections demonstrate the entire length of the median umbilical ligament as it traverses the bladder wall. Therefore, we think that documentation of urachal remnants is helpful if present, but their absence, especially in widely invasive tumors, does not preclude a urachal origin.
Three cases in our series demonstrated spread of the tumor to the surface mucosa of the bladder. All three cases showed the presence of urachal remnants with transition from benign to adenomatous epithelium. The surface involvement by tumor, which can be attributed to direct extension to the bladder urothelium in continuity with the urachal orifice, would render it difficult to distinguish morphologically between a urachal carcinoma and a vesical adenocarcinoma with an in situ component showing glandular differentiation. In such a setting, the presence of underlying urachal remnants demonstrating adenomatous changes strongly favors a urachal origin. Finally, it is possible, and documented in at least 1 of our cases, that a urachal remnant based in the bladder wall may rarely communicate with the bladder lumen, a fact that makes sense on the basis of embryologic findings.
There is a considerable overlap in the immunohistochemical staining patterns of colonic adenocarcinoma and primary vesical adenocarcinoma with enteric type differentiation. 12, 21, 23 Colorectal adenocarcinoma, although classically of the CK7( À ) CK20(+) phenotype, can on occasion be CK7(+) CK20(+). 3 Positive immunoreactivity for CK7 was always found to be accompanied by positive staining for CK20. Wang et al 23 suggest that nuclear b-catenin expression is specific for colorectal adenocarcinoma. In their study, 81% of the examined colorectal adenocarcinomas had nuclear immunoreactivity, whereas none of the 17 primary vesical adenocarcinomas had nuclear immunoreactivity.
Although all the tumors we studied were strongly and diffusely CK20 positive, positive staining for CK7 was present in about half. Only two-thirds stained with 34BE12, and in the majority of these only focal staining was seen. In contrast, only 11% of colonic adenocarci-noma showed reactivity for 34BE12, as rare cells with weak 34BE12 staining. The majority (93%) of the urachal tumors had strong and diffuse cytoplasmic membranous reactivity for b-catenin, with only 1 case showing focal nuclear accentuation. On the other hand, there was nuclear accentuation in a background of cytoplasmic membranous staining in 25% of colorectal adenocarcinoma. Therefore, immunostains do not unequivocally discriminate between a urachal and a colonic malignancy, although diffuse strong immunoreactivity for 34BE12 would support and diffuse nuclear reactivity for b-catenin would militate against a diagnosis of urachal carcinoma.
The poor prognosis associated with urachal carcinoma is owing to a high frequency of locally advanced disease at presentation. In our study, 7 of 24 (29%) patients recurred locally, of which 3 were pT3a and 4 were pT3b. This is in accordance with the literature where most of the tumors that recur locally are the tumors with high stage at presentation. In our study, the majority of recurrences were in the urinary bladder (5 cases), followed by the prostate and seminal vesicles, 19 prostate with the prostatic and membranous urethra, 19 retroperitoneal soft tissue, 19 and pubic bone. 19 In the literature, the pelvis, urinary bladder, and abdominal wall are preferred sites of local recurrence. 8 Another interesting observation we make in our case series is that tumors that have an access to the vesical cavity have another mode of local relapse, namely, seeding and ''drop metastases'' in the distal urothelial tract. In the instance of case 24, where the noninvasive villous adenoma-like component had a polypoid configuration and opened into the bladder lumen, the disease had an intractable clinical course characterized by repeated recurrences in the distal urothelial tract that were not amenable to local control and thus ultimately required radical surgery.
The surgical management differed in the recent large studies reported. In the MD Anderson cancer center series, 20 only about half of patients undergoing primary surgical treatment had en bloc resection of the urachal ligament and umbilicus, with the majority of this group being long-term survivors. In the Mayo clinic series, 1 there was a 48% survival among 60 surgically treated patients, of which more than half did not undergo en bloc resection of the urachus. However, the authors observed that complete urachectomy and umbilectomy were significant predictors of survival on univariate analysis, and recommended their routine inclusion.
Three different staging systems for urachal carcinoma have been proposed: the Sheldon, 19 the Mayo systems, 1 and the Ontario systems. 16 In the previous study from our institution by Herr et al, on the basis of rate of cure after the standard surgery recommended in the same study, it was recommended that staging of primary urachal tumors might better be simply dichotomized as urachal tumor confined to the urachus, bladder, and perivesical tissue (surgical specimen) versus intraperitoneal spread of disease (a modification of the Ontario system). Only 3 cases in our study fit into the latter category. We are, therefore, reluctant to make the same staging recommendation on the basis of our smaller patient cohort.
In the current study, all cases with locally recurrent and metastatic tumors and patients who were dead of disease belonged to Sheldon pathologic stage pT3 or higher. All 3 patients who were alive with evidence of disease at last follow-up belonged to stage pT3b or higher. The 1 case with a positive soft tissue margin after the initial surgical procedure was pT3b. The 2 cases with pT2 disease remained free of disease after initial surgical treatment with 155.6 and 23.5 months follow-up, respectively. Although we were reluctant to perform a formal statistical evaluation with outcome correlation owing to the limited sample size, our results are in accordance with the literature where outcome was strongly correlated with Sheldon stage. 1, 19, 20 In summary, urachal carcinomas are rare tumors that occur predominantly in the dome of the urinary bladder. The presence of surface urothelial colonization by urachal carcinoma and the presence of cystitis cystica and glandularis does not necessarily rule out this diagnosis. Benign and adenomatous urachal remnants are helpful if present, but their absence does not preclude a urachal origin. On the basis of this, we propose the following criteria (modified from Sheldon's original criteria) for the diagnosis of urachal carcinoma: (1) location of the tumor in the dome/anterior wall, (2) epicenter of carcinoma in the bladder wall, (3) absence of widespread cystitis cystica/glandularis beyond the dome/ anterior wall, and (4) absence of a known primary elsewhere. Immunostains do not unequivocally discriminate between a urachal versus a colorectal origin, but diffuse 34BE12 positivity would support, and diffuse nuclear immunoreactivity for b-catenin would militate against a diagnosis of urachal carcinoma. The location of urachal carcinoma in the mid-outer bladder wall and frequently bulky nature account for a greater proclivity for extravesical extension into the space of Retzius and therefore for high stage disease. Hence, the surgical procedure of choice is wide pelvic dissection to encompass the umbilicus, tumor, and entire urachus, along with partial cystectomy, with achievement of negative bladder and soft tissue margins and pelvic lymph node dissection. A less well recognized mode of local recurrence, particularly in tumors with a superficial location in the bladder and access to the vesical cavity, is ''seeding'' in the lower urothelial tract and urinary bladder. The most important determinant of prognosis is Sheldon pathologic stage.
